- Research works
- 115 ▲ 177% vs 2013–17
- Citations
- 2.5k 21.6 per fractional work
- Top-10% rate
- 18.5% record average 16.5%
- Open access
- 52% world 28%
Not ranked overall: Boehringer Ingelheim (China) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 8.0×. Every wedge is a field page.
- Immunology and Microbiology 8.0×
- Veterinary 5.2×
- Medicine 3.3×
- Pharmacology, Toxicology and Pharmaceutics 2.9×
- Biochemistry, Genetics and Molecular Biology 1.5×
- Mathematics 1.3×
- Decision Sciences 1.2×
- Agricultural and Biological Sciences 1.2×
- Nursing 1.1×
- Chemistry 0.9×
- Economics, Econometrics and Finance 0.4×
- Neuroscience 0.4×
- Health Professions 0.4×
- Psychology 0.3×
- Computer Science 0.3×
- Dentistry 0.1×
- Arts and Humanities 0.1×
- Environmental Science 0.1×
- Engineering 0.1×
- Social Sciences 0.0×
- Materials Science 0.0×
Which keywords describe research at Boehringer Ingelheim (China)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: TGF-ß, Heart Failure, Epidemiology, Fibrosis, Glycemic Control, Insulin Therapy, Regulatory T Cells and Immune System.
- Targeted Therapy
- Echocardiography
- Metagenomics
- Genomic Sequencing
- Chronic Kidney Disease
- Immune Response
- Myofibroblast
- Vaccine
- Interstitial Lung Disease
- Cardiovascular Outcomes
- Treatment
- Type 2 Diabetes
- Immunosuppressive Therapy
- TH17 Cells
- Immune System
- Diagnosis
- Regulatory T Cells
- Insulin Therapy
- Fibrosis
- TGF-ß
- Epidemiology
- Heart Failure
- Glycemic Control
- Cardiovascular Disease
- Clinical Trials
- IL-17
- Obesity
- Clinical Guidelines
- Pathogenesis
- Inflammation
- Autoantibodies
- Glucose Control
- Quality of Life
- Idiopathic Pulmonary Fibrosis
- Chemotherapy
- Metabolic Syndrome
- Coronavirus
- Immune Dysregulation
- Circovirus
- Porcine Reproductive and Respiratory Syndrome Virus
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology5▲ 3.1×31 topics
- TGF-ß4▲ 68×4 topics
- Heart Failure4▲ 22×7 topics
- Fibrosis3▲ 35×4 topics
- Glycemic Control3▲ 40×4 topics
- Insulin Therapy2▲ 48×3 topics
- Cardiovascular Disease2▲ 5.0×14 topics
- Regulatory T Cells2▲ 48×3 topics
- Clinical Trials2▲ 8.0×9 topics
- Diagnosis2▲ 5.7×11 topics
- IL-172▲ 157×1 topic
- Immune System2▲ 22×3 topics
- Obesity2▲ 7.0×12 topics
- TH17 Cells2▲ 157×1 topic
- Clinical Guidelines2▲ 17×4 topics
- Immunosuppressive Therapy2▲ 27×4 topics
- Pathogenesis2▲ 9.4×9 topics
- Type 2 Diabetes2▲ 22×3 topics
- Inflammation2▲ 2.2×22 topics
- Treatment2▲ 3.9×10 topics
- Autoantibodies2▲ 19×6 topics
- Cardiovascular Outcomes2▲ 83×1 topic
- Glucose Control2▲ 83×1 topic
- Interstitial Lung Disease2▲ 71×2 topics
- Quality of Life2▲ 3.0×10 topics
- Vaccine2▲ 10×5 topics
- Idiopathic Pulmonary Fibrosis2▲ 82×1 topic
- Myofibroblast2▲ 82×1 topic
- Chemotherapy2▲ 5.1×9 topics
- Immune Response2▲ 6.0×8 topics
- Metabolic Syndrome2▲ 4.3×10 topics
- Chronic Kidney Disease1▲ 13×7 topics
- Coronavirus1▲ 13×2 topics
- Genomic Sequencing1▲ 25×2 topics
- Immune Dysregulation1▲ 34×2 topics
- Metagenomics1▲ 31×2 topics
- Circovirus1▲ 80×1 topic
- Echocardiography1▲ 9.3×4 topics
- Porcine Reproductive and Respiratory Syndrome Virus1▲ 80×1 topic
- Targeted Therapy1▲ 11×4 topics
Which research topics does Boehringer Ingelheim (China) publish most on?
By volume in 2022–2025: Psoriasis: Treatment and Pathogenesis, Diabetes Treatment and Management, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis and Animal Virus Infections Studies.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Psoriasis: Treatment and Pathogenesis Immunology 2 works
- 2 Diabetes Treatment and Management Endocrinology, Diabetes and Metabolism 2 works
- 3 Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Pulmonary and Respiratory Medicine 2 works
- 4 Animal Virus Infections Studies Animal Science and Zoology 1 works
- 5 Dermatology and Skin Diseases Dermatology 1 works
- 6 Animal Disease Management and Epidemiology Agronomy and Crop Science 1 works
- 7 Heart Failure Treatment and Management Cardiology and Cardiovascular Medicine 1 works
- 8 Cardiovascular Function and Risk Factors Cardiology and Cardiovascular Medicine 1 works
- 9 Viral Infections and Immunology Research Cardiology and Cardiovascular Medicine 1 works
- 10 Autoimmune Bullous Skin Diseases Pathology and Forensic Medicine 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Boehringer Ingelheim (China)'s research output changed?
Output in 2018–2022 was 177% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Hong Kong
- Hong Kong Polytechnic University
- Chinese University of Hong Kong
- City University of Hong Kong
- Hong Kong University of Science and Technology
- Hong Kong Baptist University
- Queen Mary Hospital
- Hong Kong Metropolitan University
- Queen Elizabeth Hospital
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.